|[April 23, 2012]
BioTime's Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen® Product Development
ALAMEDA, Calif. --(Business Wire)--
BioTime, Inc. (NYSE Amex: BTX) announced today that Charles S. Irving,
Ph.D., the CEO of BioTime's subsidiary Cell Cure Neurosciences, Ltd.
will provide an update on the development of OpRegen® at an
investor meeting in New York City. In his presentation, Dr. Irving will
describe the unmet medical needs and markets for the treatment of the
dry form of age-related macular degeneration (AMD (News - Alert)), and the advantages
of Cell Cure's OpRegen which has been produced from human embryonic stem
cells in culture conditions free of animal products, eliminating the
need for designating the product as a xenotransplantation therapeutic.
Dr. Irving will also discuss Cell Cure's collaboration with Teva
Pharmaceutical Industries Ltd., under which Teva has the option to
develop and commercialize both OpRegen® and OpRegen-Plus®.
Dr. Irving will describe the nature of the ongoing preclinical studies
which are expected to lead to regulatory filings for the initiation of
human clinical trials in 2013. Dr. Irving's presentation will be
available on BioTime's web site www.biotimeinc.com
as well as Cell Cure Neuroscience's web site at www.cellcureneurosciences.com.
Age-related macular degeneration is the leading cause of blindness in an
aging population. It is widely believed that the loss or dysfunction of
a particular type of cell called "retinal pigment epithelial" (RPE)
cells is the root cause of the disease. While therapies exist to treat
what is called the "wet form" of macular degeneration exist, there are
no therapies for the "dry form". The transplantation of healthy RPE
cells may provide a superior treatment for this devastating disorder.
Cell Cure's OpRegen® is "xeno-free", meaning that no animal
products were used in the culture of the human embryonic stem
cell-derived RPE cells. The use animal products to culture cells often
results in the designation of the therapy as a "xenotransplantation"
product, even though the cells themselves are of human origin.
Xenotransplantation may raise purity issues, increasing the costs of
product development along with other risks and uncertainties. The
production of animal product-free OpRegen® will therefore
eliminate concerns of xenotransplantation and may provide cost savings
in development and production should the product successfully complete
clinical trials and be approved for human use.
About Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. was established in 2005 as a subsidiary of
ES Cell International Pte Ltd (ESI (News - Alert)), now a subsidiary of BioTime, Inc.
(NYSE Amex:BTX). Cell Cure is located in Jerusalem, Israel on the campus
of Hadassah Univesity Hospital. Cell Cure's mission is to become a
leading supplier of human cell-based therapies for the treatment of
retinal and neural degenerative diseases. Its technology platform is
based on the manufacture of diverse cell products sourced from clinical
grade (GMP) human embryonic stem cells. Its current programs include
developing cells for the treatment of macular degeneration, Parkinson's
disease, and cells potentially useful in treating multiple sclerosis.
Cell Cure's major shareholders include: BioTime Inc. (NYSE Amex:BTX),
Hadasit BioHoldings Ltd. (Tel Aviv Stock Exchange:HDST) and Teva
Pharmaceuticals Industries Ltd (NASDAQ:TEVA).
Additional information about Cell Cure can be found on the web at www.cellcureneurosciences.com.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is developed
through subsidiaries focused on specific fields of applications. BioTime
develops and markets research products in the field of stem cells and
regenerative medicine, including a wide array of proprietary
ACTCellerate™ cell lines, culture media, and differentiation kits.
BioTime's wholly owned subsidiary ES Cell International Pte. Ltd. has
produced clinical-grade human embryonic stem cell lines that were
derived following principles of Good Manufacturing Practice and
currently offers them for use in research. BioTime's therapeutic product
development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high
unmet medical need. BioTime's majority owned subsidiary Cell Cure
Neurosciences, Ltd. is developing therapeutic products derived from stem
cells for the treatment of retinal and neural degenerative diseases.
Cell Cure's minority shareholder Teva Pharmaceutical Industries has an
option to clinically develop and commercialize Cell Cure's OpRegen™
retinal cell product for use in the treatment of age-related macular
degeneration. BioTime's subsidiary OrthoCyte Corporation is developing
therapeutic applications of stem cells to treat orthopedic diseases and
injuries. Another subsidiary, OncoCyte Corporation, focuses on the
diagnostic and therapeutic applications of stem cell technology in
cancer, including the diagnostic product PanC-DxTM
currently being developed for the detection of cancer in blood samples,
and therapeutic strategies using vascular progenitor cells engineered to
destroy malignant tumors. ReCyte Therapeutics, Inc. is developing
applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's newest subsidiary,
LifeMap Sciences, Inc., is developing an online database of the complex
cell lineages arising from stem cells to guide basic research and to
market BioTime's research products. In addition to its stem cell
products, BioTime develops blood plasma volume expanders, blood
replacement solutions for hypothermic (low-temperature) surgery, and
technology for use in surgery, emergency trauma treatment and other
applications. BioTime's lead product, Hextend®, is a blood plasma volume
expander manufactured and distributed in the U.S. by Hospira, Inc. and
in South Korea by CJ CheilJedang Corp. under exclusive licensing
agreements. Additional information about BioTime, ReCyte Therapeutics,
Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, LifeMap Sciences, and ESI
can be found on the web at www.biotimeinc.com.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts
[ Back To Contact Center Solutions Homepage's Homepage ]